Laura H. Bukkems

Leiden, ZH 2333ZA, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

From Clinical Trials to Real-World Patients: Population Pharmacokinetics and Precision Dosing Simulations of Lorlatinib.

From Clinical Trials to Real-World Patients: Population Pharmacokinetics and Precision Dosing Simulations of Lorlatinib.

Journal: Clinical pharmacokinetics

Published: May 20, 2026

Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Journal: Clinical pharmacokinetics

Published: May 19, 2026

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.

Model-informed approaches to develop drug cost-saving dosing strategies for pembrolizumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 10, 2026

Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Journal: Clinical pharmacokinetics

Published: March 12, 2026

Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Journal: Clinical pharmacokinetics

Published: October 01, 2025

Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness.

Journal: Clinical pharmacokinetics

Published: October 01, 2025

Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B.

Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B.

Journal: Research and practice in thrombosis and haemostasis

Published: March 12, 2024

A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.

A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.

Journal: British journal of clinical pharmacology

Published: May 25, 2023

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation.

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation.

Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

Published: April 11, 2023

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A.

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A.

Journal: Thrombosis and haemostasis

Published: November 19, 2022

Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report.

Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report.

Journal: Antiviral therapy

Published: September 05, 2022

Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis.

Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis.

Journal: CPT: pharmacometrics & systems pharmacology

Published: August 16, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026